These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 34135330)
21. Molecular pathology in therapeutics: where are we now, and where are we going? Harrison DJ; Faratian D Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390 [No Abstract] [Full Text] [Related]
22. Targeting the DNA Damage Response in Cancer. O'Connor MJ Mol Cell; 2015 Nov; 60(4):547-60. PubMed ID: 26590714 [TBL] [Abstract][Full Text] [Related]
23. Exclusive destruction of mitotic spindles in human cancer cells. Visochek L; Castiel A; Mittelman L; Elkin M; Atias D; Golan T; Izraeli S; Peretz T; Cohen-Armon M Oncotarget; 2017 Mar; 8(13):20813-20824. PubMed ID: 28209915 [TBL] [Abstract][Full Text] [Related]
24. Is Precision Medicine an Oxymoron? Eckhardt SG; Lieu C JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105 [No Abstract] [Full Text] [Related]
25. New ESMO scale ranks mutations as cancer medicine targets. Fricker J Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495 [No Abstract] [Full Text] [Related]
26. A good molecular target for prostate cancer chemotherapy. Grimes SR Asian J Androl; 2011 Mar; 13(2):207. PubMed ID: 21317914 [No Abstract] [Full Text] [Related]
27. Transient endoreplication down-regulates the kinesin-14 HSET and contributes to genomic instability. Chen S; Stout JR; Dharmaiah S; Yde S; Calvi BR; Walczak CE Mol Biol Cell; 2016 Oct; 27(19):2911-23. PubMed ID: 27489338 [TBL] [Abstract][Full Text] [Related]
28. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Italiano A Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746 [TBL] [Abstract][Full Text] [Related]
29. Delivering on the promise of precision cancer medicine. Berger MF; Van Allen EM Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852 [No Abstract] [Full Text] [Related]
32. Maurie Markman on the Groundbreaking TAPUR Trial. Markman M Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751 [No Abstract] [Full Text] [Related]
33. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics. Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335 [No Abstract] [Full Text] [Related]
34. Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer. Schouten PC; Linn SC J Clin Oncol; 2015 Jun; 33(17):1867-9. PubMed ID: 25918281 [No Abstract] [Full Text] [Related]
35. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Dienstmann R; Jang IS; Bot B; Friend S; Guinney J Cancer Discov; 2015 Feb; 5(2):118-23. PubMed ID: 25656898 [TBL] [Abstract][Full Text] [Related]
36. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Yan Y; Zuo X; Wei D Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504 [TBL] [Abstract][Full Text] [Related]
37. Autophagy in cancer and chemotherapy. Yousefi S; Simon HU Results Probl Cell Differ; 2009; 49():183-90. PubMed ID: 19142622 [TBL] [Abstract][Full Text] [Related]